Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label
机构：[1]Hebei Med Univ, Hosp 4, Hebei Canc Hosp, Breast Ctr, East Campus, Shijiazhuang, Hebei, Peoples R China临床科室外一科河北医科大学第四医院[2]Shanxi Canc Hosp, Breast Ctr, Taiyuan, Peoples R China[3]Xintai Renming Hosp, Breast Ctr, Xintai, Peoples R China
第一作者机构：[1]Hebei Med Univ, Hosp 4, Hebei Canc Hosp, Breast Ctr, East Campus, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Song Z.,Wang H.,Yang Q.,et al.Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label[J].ANNALS OF ONCOLOGY.2021,32:S437-S437.doi:10.1016/j.annonc.2021.08.462.
APA：
Song, Z.,Wang, H.,Yang, Q.,Li, Y.,Qi, Y....&Yang, C..(2021).Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label.ANNALS OF ONCOLOGY,32,
MLA：
Song, Z.,et al."Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label".ANNALS OF ONCOLOGY 32.(2021):S437-S437
医学